Clinical Trial

To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004

Name: To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004 — clinical trial record (NCT07245251)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This is a single-arm, single-center, open-label, multiple-dose, dose-escalation early clinical study aimed at evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor activity of STR-P004 in subjects with relapsed/refractory CD19-positive acute lymphoblastic leukemia.

Trial Details

NCT Number	NCT07245251
Lead Sponsor	Starna Therapeutics
Conditions	Acute Lymphobkastic Leukemia
Enrollment	11 participants
Start Date	2025-12-03
Primary Completion	2026-11-02 (estimated)
Study Completion	2026-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-24